Guardians for health
sA global initiative to reduce mortality, cardiovascular and kidney complications in type 2 diabetes through adherence to clinical guideline.
Szukaj
Boehringer Ingelheim - Z pasją działamy na rzecz poprawy zdrowia
Boehringer Ingelheim to wiodąca firma farmaceutyczna, stawiająca na innowacje i kierująca się chęcią poprawy zdrowia ludzi i zwierząt. Dowiedz się węcej.
More Potential Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Championing novel science
Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.
„Going beyond” Jak lekarze weterynarii przekraczają granice
„Going beyond” Jak lekarze weterynarii przekraczają granice
Antibody therapeutics business partnering PetMedix
Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.
Our Innovation Strategy
Our discovery research strategy is designed to sustain our track record of innovation and look for new and breakthrough medicines.
Supporting grooms in equestrian sports
Find out how one organization can change the lives of those who dedicate their careers to horse care.
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Kodeks postępowania dostawców
BI’s expectations towards its suppliers on ethical behavior, integrity, professionalism and common business requirements.
Ujawnienie informacji wymaganych przez EFPIA
Przejrzystość jest podstawowym fundamentem zaufania w branży medycznej
More Green Overview
Our pillar MORE GREEN encompasses environmental initiatives that consider many different aspects.
Aftopor®/Aftovaxpur®/Aftovax®/Aftobov®Oleosa/Aftovaxpur®Doe
FMD vaccines with highly potent and purified antigens (Aftopor®, Aftovaxpur®, Aftobov® Oleosa) allow differentiation between infected and vaccinated animals for endemic or emergency situations.
2023 06 BI English methodological note
Informacja o przetwarzaniu danych osobowych przez Boehringer Ingelheim Sp. z o.o. w związku ze współpracą z Partnerami Biznesowymi
Informacja o przetwarzaniu danych osobowych przez Boehringer Ingelheim Sp. z o.o. w związku z współpracą z Partnerami Biznesowymi
Praxbind ChPL
Praxbind_Ulotka
2024_01_31_BI_PL_Methodological note_PAGs.2023
2023_06_16_BI_PL_Methodological note_PAGs.2022
OWU PL-EN BI GBS Wro 2024
View from Both Sides of the Table
Stawiamy na zarządzanie aliansami
Submit Your Opportunity
Information on how to submit a partnering opportunity direct to Boehringer Ingelheim’s Business Development & Licensing team
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
We’re All In
Watch our video to learn about our approach to innovation and partnerships